Lv1
29 积分 2022-10-26 加入
Optimal paricalcitol starting dose for parathyroid hormone suppression in secondary hyperparathyroidism
2天前
求助中
Model Informed Pediatric Development Applied to Bilastine: Ontogenic PK Model Development, Dose Selection for First Time in Children and PK Study Design
6天前
已完结
Safety and efficacy of bilastine: a new H1-antihistamine for the treatment of allergic rhinoconjunctivitis and urticaria
6天前
已完结
Paricalcitol Capsule for the Treatment of Secondary Hyperparathyroidism in Stages 3 and 4 CKD
8天前
已完结
PET/CT study of dopamine transporter (DAT) binding with the triple reuptake inhibitor toludesvenlafaxine in rats and humans
13天前
已完结
Pregabalin controlled-release pharmacokinetics in healthy volunteers: analysis of four multiple-dose randomized clinical pharmacology studies
14天前
已完结
A new analog of 1,25-(OH)2D3, 19-NOR-1,25-(OH)2D2, suppresses serum PTH and parathyroid gland growth in uremic rats without elevation of intestinal vitamin D receptor content
15天前
已完结
COMPARISON OF PLASMA PROTEIN BINDING OF BASIC DRUGS IN BLACK AND WHITE INDIVIDUALS
17天前
已完结
Differences in plasma binding of drugs between Caucasians and Chinese subjects
17天前
已完结
Omeprazole as a CYP2C19 Marker in Chinese Subjects: Assessment of Its Gene‐Dose Effect and Intrasubject Variability
22天前
已完结
皖公网安备34019202002308
